LBRX
NASDAQLB Pharmaceuticals Inc
Price$28.55+4.17 (+17.10%)
2026-03-042026-06-05
News · 26 weeks46-11%
2025-12-142026-06-07
Mix3290d
- SEC Filings13(41%)
- Insider9(28%)
- Other6(19%)
- Analyst2(6%)
- Offering1(3%)
- Leadership1(3%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Ruffolo Robert R4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
- INSIDERSEC Form 4 filed by Director Nussbaum Ran4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
- INSIDERSEC Form 4 filed by Director Luse Rebecca4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
- INSIDERSEC Form 4 filed by Director Lenz Robert A.4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
- INSIDERSEC Form 4 filed by Director Hemrajani Rekha4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
- INSIDERSEC Form 4 filed by Director Kane William P Jr4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
- INSIDERSEC Form 4 filed by Director Garland J. Scott4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
- PRLB Pharmaceuticals to Participate in Upcoming June Investor EventsNEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder, and other neuropsychiatric diseases, today announced that members of its executive team, will present and participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference Date: Thursday, June 4, 2026 Time: 2:35 p.m. ET H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference Date: Tuesday, June 16, 2026 Time: Presentation available on the LB Pharmaceuticals w
- SECAmendment: SEC Form SCHEDULE 13G/A filed by LB Pharmaceuticals IncSCHEDULE 13G/A - LB PHARMACEUTICALS INC (0001691082) (Subject)
- SECSEC Form 424B3 filed by LB Pharmaceuticals Inc424B3 - LB PHARMACEUTICALS INC (0001691082) (Filer)
- SECSEC Form 10-Q filed by LB Pharmaceuticals Inc10-Q - LB PHARMACEUTICALS INC (0001691082) (Filer)
- SECLB Pharmaceuticals Inc filed SEC Form 8-K: Results of Operations and Financial Condition8-K - LB PHARMACEUTICALS INC (0001691082) (Filer)
- PRLB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate UpdateInitiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression Published results from the Phase 2 NOVA-1 trial of LB-102 in schizophrenia in The Journal of the American Medical Association (JAMA) Psychiatry Expanded pipeline following $100 million private placement with plans to initiate a Phase 2 trial of LB-102 in adjunctive treatment of major depressive disorder (MDD) in early 2027 Cash, cash equivalents, and marketable securities of $365.6 million as of March 31, 2026 expected to fund operations into Q2 2029, through multiple clinical milestones NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -
- ANALYSTH.C. Wainwright initiated coverage on LB Pharmaceuticals with a new price targetH.C. Wainwright initiated coverage of LB Pharmaceuticals with a rating of Buy and set a new price target of $45.00
- SECSEC Form DEFA14A filed by LB Pharmaceuticals IncDEFA14A - LB PHARMACEUTICALS INC (0001691082) (Filer)
- SECSEC Form DEF 14A filed by LB Pharmaceuticals IncDEF 14A - LB PHARMACEUTICALS INC (0001691082) (Filer)
- PRLB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in SchizophreniaPivotal Phase 3 NOVA-2 trial in schizophrenia ongoing, topline data expected in 2H 2027LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD), and other neuropsychiatric diseases, today announced the publication in the Journal of the American Medical Association (JAMA) Psychiatry of its manuscript titled "Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adults with Acute Schizo
- SECSEC Form EFFECT filed by LB Pharmaceuticals IncEFFECT - LB PHARMACEUTICALS INC (0001691082) (Filer)
- SECSEC Form 424B3 filed by LB Pharmaceuticals Inc424B3 - LB PHARMACEUTICALS INC (0001691082) (Filer)
- ANALYSTCraig Hallum initiated coverage on LB Pharmaceuticals with a new price targetCraig Hallum initiated coverage of LB Pharmaceuticals with a rating of Buy and set a new price target of $36.00
- PRLB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare ConferenceNEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD) and other neuropsychiatric diseases, today announced that Heather Turner, Chief Executive Officer, will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2026, at 11:45 a.m. ET. A live webcast of the presentation will be available on the "Investors" page under the "Events" section of the Company's website at https://ir.lbpharma.us/investors/events/, where a replay of the webcast will b
- SECSEC Form S-1 filed by LB Pharmaceuticals IncS-1 - LB PHARMACEUTICALS INC (0001691082) (Filer)
- PRLB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102's Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder (MDD), and other neuropsychiatric diseases, today announced the presentation of new data further evaluating the effects of LB-102 on cognitive performance in the Phase 2 NOVA-1 clinical trial in patients with acute schizophrenia. LB-102, a novel, once-daily, oral investigational small molecule, is a selective antagonist of D2, D3, and 5HT7 receptors that is being advanced as a potential first benzamide antipsychotic
- SECSEC Form S-8 filed by LB Pharmaceuticals IncS-8 - LB PHARMACEUTICALS INC (0001691082) (Filer)
- SECSEC Form 10-K filed by LB Pharmaceuticals Inc10-K - LB PHARMACEUTICALS INC (0001691082) (Filer)
LBRX FAQ
6 questionsWhere does LBRX stock trade?
LB Pharmaceuticals Inc (LBRX) is listed on NASDAQ.What sector and industry is LBRX in?
LB Pharmaceuticals Inc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did LB Pharmaceuticals Inc go public?
LB Pharmaceuticals Inc (LBRX) completed its IPO in 2025.What are analysts saying about LBRX?
LB Pharmaceuticals Inc has had 6 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $4500.00 price target on 2026-04-27. Recent price targets range from $2700.00 to $4500.00.What companies are similar to LBRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare LBRX side-by-side with any of them on Quantisnow.How can I track LBRX on Quantisnow?
Quantisnow aggregates LB Pharmaceuticals Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LBRX to receive live email and push alerts on every new disclosure.